Bio-Techne Shares Fall Despite Earnings Beat

Bio-Techne (TECH) reported fourth-quarter adjusted earnings per share of $0.53 and revenues of $316.96 million, both beating analyst estimates, with growth driven by its protein sciences unit despite a slight decline in diagnostics and spatial biology. However, company shares have dropped significantly in 2025 as investors worry about the impact of U.S. tariffs, academic funding reductions, and proposed drug pricing reforms. Management expects these uncertainties to limit Bio-Techne's growth to low single digits until more policy clarity emerges. The company is refocusing on higher-growth areas, highlighted by the sale of its Exosome Diagnostics business to Mdxhealth SA. Additionally, biote Corp. (BTMD) beat earnings expectations but missed on revenue and has underperformed the broader market, with its shares down 32.5% year-to-date. The sector continues to face headwinds despite outperforming earnings.